News and Press Releases
Press releases
Rutherrin® Demonstrates Complete Response in Lung Cancer Preclinically
June 19, 2024 - Rutherrin®, has demonstrated an ability to provide a complete response in a Non-Small Cell Lung Cancer (“NSCLC”) animal model....
0Rutherrin® Increases Efficacy of Immunotherapy Preclinically
June 18, 2024 - Rutherrin®, in preclinical research, has demonstrated an ability to increase the efficacy of immunotherapy....
0Reminder Notice of Annual General and Special Meeting for Shareholders of Theralase®
June 14, 2024 - Reminder Notice of Annual General and Special Meeting on June 19, 2024 at 4:30 pm after the formal part of the meeting a virtual...
0Rutherrin® Increases Efficacy of Chemotherapy
June 12, 2024 - Rutherrin® has been proven in preclinical studies to enhance the efficacy of chemotherapy and reduce multidrug resistance....
0Ruvidar Enhances Efficacy of Cancer Drug
June 10, 2024 - Ruvidar™, in combination with Bacillus Calmette-Guérin (BCG), significantly enhances the cancer cell-killing efficacy...
0Theralase® Successfully Destroys Lung Cancer
June 6, 2024 - Rutherrin®, has been proven effective preclinically in the destruction of Non-Small Cell Lung Cancer (“NSCLC”)....
0Theralase® Technology Effective in Virus Inactivation
June 4, 2024 - Theralase's lead compound, Ruvidar, has been proven effective in the inactivation of various viruses. The research was completed...
0Theralase® Release’s 1Q2024 Financial Statements
May 30, 2024 - Theralase releases the Company's unaudited interim consolidated 1Q2024 Financial Statements...
0Theralase® Expands Clinical Team
May 2, 2024 - Theralase expands its clinical team with the hiring of two Clinical Research Associates....
0Theralase® Closes $CAN 750,000 Non-Brokered Private Placement
April 24, 2024 - Theralase closes Non-Brokered Private Placement of units for gross proceeds of $CAN 750,200....
0in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.